A citation-based method for searching scientific literature

Veena Sangkhae, S Leah Etheridge, Kenneth Kaushansky, Ian S Hitchcock. Blood 2014
Times Cited: 57







List of co-cited articles
713 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Somatic mutations of calreticulin in myeloproliferative neoplasms.
Thorsten Klampfl, Heinz Gisslinger, Ashot S Harutyunyan, Harini Nivarthi, Elisa Rumi, Jelena D Milosevic, Nicole C C Them, Tiina Berg, Bettina Gisslinger, Daniela Pietra,[...]. N Engl J Med 2013
54

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Yana Pikman, Benjamin H Lee, Thomas Mercher, Elizabeth McDowell, Benjamin L Ebert, Maricel Gozo, Adam Cuker, Gerlinde Wernig, Sandra Moore, Ilene Galinsky,[...]. PLoS Med 2006
50

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
Chloé James, Valérie Ugo, Jean-Pierre Le Couédic, Judith Staerk, François Delhommeau, Catherine Lacout, Loïc Garçon, Hana Raslova, Roland Berger, Annelise Bennaceur-Griscelli,[...]. Nature 2005
50

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L Levine, Martha Wadleigh, Jan Cools, Benjamin L Ebert, Gerlinde Wernig, Brian J P Huntly, Titus J Boggon, Iwona Wlodarska, Jennifer J Clark, Sandra Moore,[...]. Cancer Cell 2005
47

A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Robert Kralovics, Francesco Passamonti, Andreas S Buser, Soon-Siong Teo, Ralph Tiedt, Jakob R Passweg, Andre Tichelli, Mario Cazzola, Radek C Skoda. N Engl J Med 2005
45

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
J Nangalia, C E Massie, E J Baxter, F L Nice, G Gundem, D C Wedge, E Avezov, J Li, K Kollmann, D G Kent,[...]. N Engl J Med 2013
45

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
E Joanna Baxter, Linda M Scott, Peter J Campbell, Clare East, Nasios Fourouclas, Soheila Swanton, George S Vassiliou, Anthony J Bench, Elaine M Boyd, Natasha Curtin,[...]. Lancet 2005
42

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.
Ralph Tiedt, Hui Hao-Shen, Marta A Sobas, Renate Looser, Stephan Dirnhofer, Jürg Schwaller, Radek C Skoda. Blood 2008
343
38

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Ilyas Chachoua, Christian Pecquet, Mira El-Khoury, Harini Nivarthi, Roxana-Irina Albu, Caroline Marty, Vitalina Gryshkova, Jean-Philippe Defour, Gaëlle Vertenoeil, Anna Ngo,[...]. Blood 2016
214
38

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Shannon Elf, Nouran S Abdelfattah, Edwin Chen, Javier Perales-Patón, Emily A Rosen, Amy Ko, Fabian Peisker, Natalie Florescu, Silvia Giannini, Ofir Wolach,[...]. Cancer Discov 2016
172
36

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Linda M Scott, Wei Tong, Ross L Levine, Mike A Scott, Philip A Beer, Michael R Stratton, P Andrew Futreal, Wendy N Erber, Mary Frances McMullin, Claire N Harrison,[...]. N Engl J Med 2007
893
31

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.
Jianmin Ding, Hirokazu Komatsu, Atsushi Wakita, Miyuki Kato-Uranishi, Masato Ito, Atsushi Satoh, Kazuya Tsuboi, Masakazu Nitta, Hiroshi Miyazaki, Shinsuke Iida,[...]. Blood 2004
239
31

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
Ann Mullally, Steven W Lane, Brian Ball, Christine Megerdichian, Rachel Okabe, Fatima Al-Shahrour, Mahnaz Paktinat, J Erika Haydu, Elizabeth Housman, Allegra M Lord,[...]. Cancer Cell 2010
270
31

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Xiaohui Lu, Ross Levine, Wei Tong, Gerlinde Wernig, Yana Pikman, Sara Zarnegar, D Gary Gilliland, Harvey Lodish. Proc Natl Acad Sci U S A 2005
252
31

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Caroline Marty, Christian Pecquet, Harini Nivarthi, Mira El-Khoury, Ilyas Chachoua, Micheline Tulliez, Jean-Luc Villeval, Hana Raslova, Robert Kralovics, Stefan N Constantinescu,[...]. Blood 2016
179
31

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Marito Araki, Yinjie Yang, Nami Masubuchi, Yumi Hironaka, Hiraku Takei, Soji Morishita, Yoshihisa Mizukami, Shin Kan, Shuichi Shirane, Yoko Edahiro,[...]. Blood 2016
174
28

Effect of mutation order on myeloproliferative neoplasms.
Christina A Ortmann, David G Kent, Jyoti Nangalia, Yvonne Silber, David C Wedge, Jacob Grinfeld, E Joanna Baxter, Charles E Massie, Elli Papaemmanuil, Suraj Menon,[...]. N Engl J Med 2015
328
26

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
Gerlinde Wernig, Thomas Mercher, Rachel Okabe, Ross L Levine, Benjamin H Lee, D Gary Gilliland. Blood 2006
382
26

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.
Juan Li, Dominik Spensberger, Jong Sook Ahn, Shubha Anand, Philip A Beer, Cedric Ghevaert, Edwin Chen, Ariel Forrai, Linda M Scott, Rita Ferreira,[...]. Blood 2010
161
26

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Animesh D Pardanani, Ross L Levine, Terra Lasho, Yana Pikman, Ruben A Mesa, Martha Wadleigh, David P Steensma, Michelle A Elliott, Alexandra P Wolanskyj, William J Hogan,[...]. Blood 2006
764
24

Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.
Lorena Arranz, Abel Sánchez-Aguilera, Daniel Martín-Pérez, Joan Isern, Xavier Langa, Alexandar Tzankov, Pontus Lundberg, Sandra Muntión, Yi-Shiuan Tzeng, Dar-Ming Lai,[...]. Nature 2014
285
24

Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells.
Hong Qian, Natalija Buza-Vidas, Craig D Hyland, Christina T Jensen, Jennifer Antonchuk, Robert Månsson, Lina A Thoren, Marja Ekblom, Warren S Alexander, Sten Eirik W Jacobsen. Cell Stem Cell 2007
361
24

Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche.
Hiroki Yoshihara, Fumio Arai, Kentaro Hosokawa, Tetsuya Hagiwara, Keiyo Takubo, Yuka Nakamura, Yumiko Gomei, Hiroko Iwasaki, Sahoko Matsuoka, Kana Miyamoto,[...]. Cell Stem Cell 2007
517
22

JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.
S Leah Etheridge, Michelle E Roh, Megan E Cosgrove, Veena Sangkhae, Norma E Fox, Junmei Chen, José A López, Kenneth Kaushansky, Ian S Hitchcock. Proc Natl Acad Sci U S A 2014
60
22

JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.
Juan Li, David G Kent, Anna L Godfrey, Harriet Manning, Jyoti Nangalia, Athar Aziz, Edwin Chen, Kourosh Saeb-Parsy, Juergen Fink, Rachel Sneade,[...]. Blood 2014
65
22

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
Jelena D Milosevic Feenstra, Harini Nivarthi, Heinz Gisslinger, Emilie Leroy, Elisa Rumi, Ilyas Chachoua, Klaudia Bagienski, Blanka Kubesova, Daniela Pietra, Bettina Gisslinger,[...]. Blood 2016
167
22

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Elisa Rumi, Daniela Pietra, Virginia Ferretti, Thorsten Klampfl, Ashot S Harutyunyan, Jelena D Milosevic, Nicole C C Them, Tiina Berg, Chiara Elena, Ilaria C Casetti,[...]. Blood 2014
403
21

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Heinz Gisslinger, Roger Waltzman, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S Hunter, Richard Levy, Laurent Knoops,[...]. N Engl J Med 2012
21

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.
Catherine Lacout, Didier F Pisani, Micheline Tulliez, Françoise Moreau Gachelin, William Vainchenker, Jean-Luc Villeval. Blood 2006
334
21

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser, Hui Hao-Shen, Ina Nissen, Sabine Girsberger, Thomas Lehmann, Jakob Passweg, Martin Stern,[...]. Blood 2014
410
21

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Richard S Levy, Vikas Gupta, John F DiPersio, John V Catalano, Michael Deininger, Carole Miller, Richard T Silver,[...]. N Engl J Med 2012
21

SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells.
Mark J Kiel, Omer H Yilmaz, Toshihide Iwashita, Osman H Yilmaz, Cox Terhorst, Sean J Morrison. Cell 2005
19

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
Raajit Rampal, Fatima Al-Shahrour, Omar Abdel-Wahab, Jay P Patel, Jean-Philippe Brunel, Craig H Mermel, Adam J Bass, Jennifer Pretz, Jihae Ahn, Todd Hricik,[...]. Blood 2014
266
19

Critical requirement for Stat5 in a mouse model of polycythemia vera.
Dongqing Yan, Robert E Hutchison, Golam Mohi. Blood 2012
97
19

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
Hajime Akada, Dongqing Yan, Haiying Zou, Steven Fiering, Robert E Hutchison, M Golam Mohi. Blood 2010
192
19

Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation.
Ashley P Ng, Maria Kauppi, Donald Metcalf, Craig D Hyland, Emma C Josefsson, Marion Lebois, Jian-Guo Zhang, Tracey M Baldwin, Ladina Di Rago, Douglas J Hilton,[...]. Proc Natl Acad Sci U S A 2014
87
19


Thrombopoietin receptor is required for the oncogenic function of CALR mutants.
H Nivarthi, D Chen, C Cleary, B Kubesova, R Jäger, E Bogner, C Marty, C Pecquet, W Vainchenker, S N Constantinescu,[...]. Leukemia 2016
51
21

Mutations and prognosis in primary myelofibrosis.
A M Vannucchi, T L Lasho, P Guglielmelli, F Biamonte, A Pardanani, A Pereira, C Finke, J Score, N Gangat, C Mannarelli,[...]. Leukemia 2013
506
17

Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.
Pontus Lundberg, Hitoshi Takizawa, Lucia Kubovcakova, Guoji Guo, Hui Hao-Shen, Stephan Dirnhofer, Stuart H Orkin, Markus G Manz, Radek C Skoda. J Exp Med 2014
69
17

IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.
Lukas F Mager, Carsten Riether, Christian M Schürch, Yara Banz, Marie-Hélène Wasmer, Regula Stuber, Alexandre P Theocharides, Xiaohong Li, Yu Xia, Hirohisa Saito,[...]. J Clin Invest 2015
67
17

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Christian Pecquet, Carmen C Diaconu, Judith Staerk, Michael Girardot, Caroline Marty, Yohan Royer, Jean-Philippe Defour, Alexandra Dusa, Rodolphe Besancenot, Stephane Giraudier,[...]. Blood 2012
38
26

Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.
Xiaohui Lu, Lily Jun-Shen Huang, Harvey F Lodish. J Biol Chem 2008
106
17

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.
Shu Xing, Tina Ho Wanting, Wanming Zhao, Junfeng Ma, Shaofeng Wang, Xuesong Xu, Qingshan Li, Xueqi Fu, Mingjiang Xu, Zhizhuang Joe Zhao. Blood 2008
162
17


The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Daniel A Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J Borowitz, Michelle M Le Beau, Clara D Bloomfield, Mario Cazzola, James W Vardiman. Blood 2016
17

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin.
T Balligand, Y Achouri, C Pecquet, I Chachoua, H Nivarthi, C Marty, W Vainchenker, I Plo, R Kralovics, S N Constantinescu. Leukemia 2016
37
27

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
A Tefferi, T L Lasho, C M Finke, R A Knudson, R Ketterling, C H Hanson, M Maffioli, D Caramazza, F Passamonti, A Pardanani. Leukemia 2014
368
15

High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.
J L Villeval, K Cohen-Solal, M Tulliez, S Giraudier, J Guichard, S A Burstein, E M Cramer, W Vainchenker, F Wendling. Blood 1997
203
15

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.
Chloe James, Frederic Mazurier, Sabrina Dupont, Ronan Chaligne, Isabelle Lamrissi-Garcia, Micheline Tulliez, Eric Lippert, François-Xavier Mahon, Jean-Max Pasquet, Gabriel Etienne,[...]. Blood 2008
82
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.